A Multi-center, Open-label, Randomized, Study to Assess the Onset of Platelet Aggregation Inhibition After a Single Subcutaneous Injection of ACT-246475 in Adults With Acute Myocardial Infarction
Phase of Trial: Phase II
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs Selatogrel (Primary)
- Indications Myocardial infarction
- Focus Biomarker; Pharmacodynamics
- Sponsors Idorsia Pharmaceuticals
- 03 Sep 2019 Results published in the Idorsia Pharmaceuticals Media Release.
- 03 Sep 2019 According to an Idorsia Pharmaceuticals Media release, the positive results from this study were presented at the European Society of Cardiology 2019 Congress(ESC 2019).
- 18 Dec 2018 According to an Idorsia media release, the compny will present data from this study at upcoming scientific congress and published in scientific literature.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History